Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.

@article{Mazzolai1999AngiotensinIR,
  title={Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.},
  author={Lucia Mazzolai and Marc Maillard and Julien Rossat and J{\"u}rg Nussberger and H. R. Brunner and Michel Burnier},
  journal={Hypertension},
  year={1999},
  volume={33 3},
  pages={
          850-5
        }
}
Use of angiotensin (Ang) II AT1 receptor antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-angiotensin system in humans are lacking. In this study, the Ang II receptor blockade induced by the recommended starting dose of 3 antagonists was evaluated in normotensive subjects in a double-blind, placebo-controlled, randomized, 4-way crossover study. At 1-week intervals, 12 subjects received a single… 
Dose‐Dependent Blockade of the Angiotensin II Type 1 Receptor with Losartan in Normal Volunteers
TLDR
This study evaluated the level and duration of blockade of a pressor response to angiotensin II by 50 and 150 mg of losartan, compared with 32 mg of candesartan.
Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans
TLDR
The data demonstrate that ARBs prescribed at their recommended doses do not block renal tubular AT1 receptors as effectively as vascular receptors do, and this observation may account for the need of higher doses of ARB for renal protection.
Pharmacodynamic Studies on the Angiotensin II Type 1 Antagonists Irbesartan and Candesartan Based on Angiotensin II Dose Response in Humans
TLDR
It is suggested that for the same degree of angiotensin II antagonism, irbesartan produces a greater increase in PRA than candesartan, and these pharmacodynamic differences warrant further investigation and clarification.
Angiotensin Type 2 Receptor-Mediated Hypotension in Angiotensin Type-1 Receptor-Blocked Rats
TLDR
The results strongly suggest that the AT2 receptor induces a systemic vasodilator response mediated by NO that counterbalances the vasoconstrictor action of Ang II at the AT1 receptor.
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?
TLDR
At their maximal recommended doses, neither LOS nor TEL blocks the RAS for 24 hours; hence, the addition of an ACE inhibitor provides an additional blockade.
Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.
TLDR
UR-7247 is a long-lasting, well-tolerated AT1 receptor in healthy subjects and has a very long plasma elimination half-life, which may be due to a high but also tight binding to protein binding sites.
Irbesartan: an updated review of its use in cardiovascular disorders.
TLDR
Although the role of irbesartan as a treatment for heart failure is little clearer than it was 2 years ago, the place of the drug in the management of hypertension is now better established.
Pharmacological Differences among Angiotensin II Receptor Antagonists
  • G. Belz
  • Medicine
    Blood pressure. Supplement
  • 2001
TLDR
Comparative trials have indicated that both irbesartan and candesartan show greater clinical efficacy in lowering blood pressure than losartan, and aldosterone levels following Ang II stimulation were blunted to a greater extent, following administration of irbsartan.
Results Effects of Acute Ang II and PD Infusion on BP in AT 1 Receptor – Blocked Rats
The type-2 (AT2) angiotensin (Ang) II receptor has been characterized as potentially counterregulatory to the actions of Ang II at its type-1 (AT1) receptor. We investigated the effects of Ang II and
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
TLDR
TCV-116 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of Ang II in men.
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
TLDR
The combined administration of a standard single oral dose of an ACE inhibitor and an Ang II antagonist to mildly sodium-depleted normal subjects had a major additive effect on plasma renin rise, induced an additional mean blood pressure reduction, and had no additive effects on plasma aldosterone fall.
Original CommunicationsComparative Efficacy of Two Angiotensin II Receptor Antagonists, Irbesartan and Losartan, in Mild-to-Moderate Hypertension
TLDR
It is demonstrated that the maximally effective once-daily doses of two different AT1 receptor antagonists may result in clinically significant differences in blood pressure reductions, and therefore highlights the potential importance of the pharmacokinetic and pharmacodynamic differences between these two members of this class.
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
TLDR
It is concluded that losartan produces a dose‐dependent, effective angiotensin II blockade that is largely determined by the active metabolite EXP3174.
Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
TLDR
A longer persistence of the antagonistic effect at the receptor site than expected by the presence in plasma indicates a slow off-rate of candesartan cilexetil from in vivo receptors.
Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II
TLDR
DuP 753 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of angiotensin II in men.
Determinants of angiotensin II generation during converting enzyme inhibition.
TLDR
The ratio of plasma angiotensin II to angiotENSin I represents converting enzyme inhibition more accurately than in vitro assays, which vary considerably depending on substrates and assay conditions used.
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
In the spinal pithed rat, DuP 753, 2-n-butyl-4-chloro-5-hydroxy-methyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl) methyl] imidazole potassium salt, inhibited competitively the pressor response to
...
1
2
3
...